Background: HIV-associated diarrhea remains a significant concern with limited treatment options.
Objective: To determine the optimal dose, efficacy, and safety of crofelemer for noninfectious diarrhea.
Methods: This randomized, double-blind, phase 3 trial used a 2-stage design.
Science
December 2010